ERC-AG-LS7
ERC-AG-LS7
Programme: H2020
89 projects · €209,113,287 total EU contribution (project-level) · 102 participating organizations · 18 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€209,113,287
Countries active
Participant organizations by country (headquarters in CORDIS).
- Italy (19)
- Germany (16)
- UK (13)
- Spain (12)
- Netherlands (11)
- France (5)
- CH (4)
- SE (4)
- NO (3)
- BE (2)
- CY (2)
- DK (2)
- FI (2)
- IL (2)
- EL (1)
- HU (1)
- IE (1)
- US (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- INSERM6 projects · FR
- KU Leuven4 projects · BE
- ERASMUS MC3 projects · NL
- HELSINGIN YLIOPISTO3 projects · FI
- UEDIN3 projects · UK
- UNIVERSITY COLLEGE LONDON3 projects · —
- Leiden University Medical Center2 projects · NL
- CSIC2 projects · ES
- GERMAN CANCER RESEARCH CENTER2 projects · DE
- HSR2 projects · IT
- INGM2 projects · IT
- IRFMN2 projects · IT
Projects
Page 6 of 9
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
Multimodal Molecular Imaging MUMI · 294582 | FP7 | €2,238,616 | €2,238,616 | Details |
Image Guided Local Drug Delivery from Nanocarriers using Focused Ultrasound SOUND PHARMA · 268906 | FP7 | €2,500,000 | €2,500,000 | Details |
Dreaming of no more renal dialysis: how self-derived tissue and cells can replace renal function RESET · 268632 | FP7 | €2,493,000 | €2,493,000 | Details |
Sensitive, specific high-throughput plasma proteome analysis via ProteinSeq PROTEINSEQ · 294409 | FP7 | €2,499,600 | €2,499,600 | Details |
Epigenome and Cancer Susceptibility EPISUSCEPTIBILITY · 232635 | FP7 | €2,500,000 | €2,500,000 | Details |
Seeing through cataracts with advanced photonics SEECAT · 339228 | FP7 | €2,374,910 | €2,374,910 | Details |
Molecular Self Screening for Cervical Cancer Prevention MASS-CARE · 322986 | FP7 | €1,999,996 | €1,999,996 | Details |
Lysosomes as targets for cancer therapy LYSOSOME · 340751 | FP7 | €2,499,960 | €2,499,960 | Details |
Development of high throughput in vivo oncogenomic screening strategies in acute leukaemia ONCOGENOMICS · 249891 | FP7 | €2,249,440 | €2,249,440 | Details |
TERPENOYLATION: AN ORIGINAL CONCEPT FOR THE DISCOVERY OF NEW NANOMEDICINES TERNANOMED · 249835 | FP7 | €2,198,799 | €2,198,799 | Details |